About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Atrtm1Bal
targeted mutation 1, David Baltimore
MGI:2176600
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Atrtm1Bal/Atrtm1Bal involves: 129 * C57BL/6 MGI:2176601
ht2
Atrtm1Bal/Atr+ involves: 129 * C57BL/6 MGI:2176603
cn3
Atrtm1Bal/Atrtm2Bal
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S2/SvPas * C57BL/6 MGI:3717476
cn4
Atrtm1Bal/Atrtm2Bal
Tg(Syn1-cre)671Jxm/0
involves: 129S/SvEv * 129S2/SvPas * C57BL/6 * CBA MGI:3717477


Genotype
MGI:2176601
hm1
Allelic
Composition
Atrtm1Bal/Atrtm1Bal
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atrtm1Bal mutation (1 available); any Atr mutation (133 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging




Genotype
MGI:2176603
ht2
Allelic
Composition
Atrtm1Bal/Atr+
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atrtm1Bal mutation (1 available); any Atr mutation (133 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• incomplete incidence, 20% of animals die by 18 months; some death correlated with tumor incidence

neoplasm
• various types and age of onset




Genotype
MGI:3717476
cn3
Allelic
Composition
Atrtm1Bal/Atrtm2Bal
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
Genetic
Background
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atrtm1Bal mutation (1 available); any Atr mutation (133 available)
Atrtm2Bal mutation (1 available); any Atr mutation (133 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (6 available); any Ndor1 mutation (32 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• 1 year after tamoxifen treatment, treated mice show a 20% decrease in body weigh compared to controls (21.3 g vs 26.6 g in controls)

pigmentation
• when mice are treated with tamoxifen at 8-12 weeks of age, within 3-4 months pervasive graying of the coat is observed; no obvious phenotype is observed in controls

skeleton
• between 3 and 12 months after tamoxifen treatment, mice show significant kyphosis relative to control mice
• 1 year after tamoxifen treatment, mice show an 18% decrease in cortical bone cross-sectional area as determined by micro-CT
• 1 year after tamoxifen treatment, mice show a 46-76% reduction in trabecular bone volume as determined by micro-CT
• after tamoxifen treatment, mice begin to develop osteoporosis

endocrine/exocrine glands
• by 1-2 weeks after tamoxifen treatment, relative to controls, mice show marked suppression of thymocyte numbers which recover by 3-4 months after treatment; 6-7 months after treatment, numbers are significantly decreased again relative to controls
• hair follicles often display sebaceous gland cell hyperplasia
• mice display premature thymic involution (~1 year) after tamoxifen treatment

hematopoietic system
• by 1-2 weeks after tamoxifen treatment, relative to controls, mice show marked suppression of thymocyte numbers which recover by 3-4 months after treatment; 6-7 months after treatment, numbers are significantly decreased again relative to controls
• mice display premature thymic involution (~1 year) after tamoxifen treatment

immune system
• by 1-2 weeks after tamoxifen treatment, relative to controls, mice show marked suppression of thymocyte numbers which recover by 3-4 months after treatment; 6-7 months after treatment, numbers are significantly decreased again relative to controls
• mice display premature thymic involution (~1 year) after tamoxifen treatment
• leukocyte infiltration of the kidneys is observed in all tamoxifen-treated mice at 1 year post-treatment

liver/biliary system
• a significant increase in senescence-associated betagalactosidase-positive cells is observed in the liver 1 year after tamoxifen treatment

renal/urinary system
• leukocyte infiltration of the kidneys is observed in all tamoxifen-treated mice at 1 year post-treatment
• by 1 year after tamoxifen treatment, kidneys display atrophy
• glomerular degeneration in all kidneys of tamoxifen-treated mice at 1 year after treatment, but not in controls
• tubular degeneration in all kidneys of tamoxifen-treated mice at 1 year after treatment
• fibrotic tissue accumulates in kidneys of tamoxifen-treated mice with age

digestive/alimentary system
• 1 week after tamoxifen treatment, ~80% of villus epithelium is lost, but recovers fully by 1 months after treatment

cardiovascular system
• compared to control mice, fibrotic tissue accumulates in hearts of tamoxifen-treated mice with age

adipose tissue
• layer is reduced up to 70% in thickness 3-6 months after tamoxifen treatment

cellular
• temporary loss of proliferating cells after tamoxifen treatment is observed in intestine, skin, kidney and liver

integument
• layer is reduced up to 70% in thickness 3-6 months after tamoxifen treatment
• hair follicles often display sebaceous gland cell hyperplasia
• when mice are treated with tamoxifen at 8-12 weeks of age, within 3-4 months pervasive graying of the coat is observed; no obvious phenotype is observed in controls
• after a third round of depilation, hair regrowth does not occur or regrows predominantly gray
• when mice are treated with tamoxifen at 8-12 weeks of age, a progressive alopecia develops within 3-4 months, increasing in expressivity past 1 year of age
• single topical doses of 4-hydroxytamoxifen to skin causes alopecia and gray hair regrowth
• remaining follicles in mice >6 months display gray shafts
• after depilation in tamoxifen-treated mice, hair shaft generation is delayed and compromised in abundance and quality
• remaining hair follicles often show abnormal architecture with degeneration of dermal and epidermal structures
• significantly delayed after tamoxifen treatment
• development is delayed in anagen after tamoxifen treatment
• loss of hair follicles is observed 3-6 months after tamoxifen treatment
• following depilation in tamoxifen-treated mice, anagen phase is accompanied by widespread degenerative follicles 4 days after depilation and delay in anagen progression 8 days after depilation
• after a second round of depilation in telogen phase, hair regrowth is more sparse, with increased representation of gray hair shafts
• after a second round of depilation in telogen phase, hair regrowth is more sparse, with increased representation of gray hair shafts
• mice develop thickened epidermis 3-6 months after tamoxifen treatment




Genotype
MGI:3717477
cn4
Allelic
Composition
Atrtm1Bal/Atrtm2Bal
Tg(Syn1-cre)671Jxm/0
Genetic
Background
involves: 129S/SvEv * 129S2/SvPas * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atrtm1Bal mutation (1 available); any Atr mutation (133 available)
Atrtm2Bal mutation (1 available); any Atr mutation (133 available)
Tg(Syn1-cre)671Jxm mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
N
• tamoxifen-treated mice do not show any significant differences from controls in circadian activity, strength, motor coordination, anxiety-like behavior, learning or memory





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory